RhoVac initiates research collaboration with Lund University, Sweden
RhoVac AB ("RhoVac") announced today, August 21 2017, that the company has signed an agreement with Lund University on research collaboration on cancer stem cells and on the expression of the protein RhoC in these cells.Cancer stem cells are a population of tumor cells that is not affected by treatment with conventional cancer therapy; a tumor treated with conventional therapy can result in relapse via the activation of cancer stem cells, and therefore patients often relapse in their disease. Previous research has documented that the protein RhoC, the target protein of RhoVac’s cancer